source
- Milestone Pharmaceuticals trims 20% workforce after FDA approval as Q3 sales reach $1 millionMilestone Pharmaceuticals announced it is reducing its headcount by about one‑fifth following the recent FDA approval of its heart‑arrhythmia therapy. The cut affects roughly 20% of the company’s s…
- Arrowhead faces challenges as Ionis's Tryngolza sales fall short, putting sHTG launch at riskIonis Pharmaceuticals reported flat sales of its severe hypertriglyceridemia drug Tryngolza, generating only $9 million and cutting its annual revenue outlook to $50 million. The weak performance…